Immunovant Inc (IMVT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunovant Inc (IMVT) has a cash flow conversion efficiency ratio of -0.169x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-124.41 Million) by net assets ($735.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IMVT stock market capitalisation for the company's overall valuation and market capitalisation.
Immunovant Inc - Cash Flow Conversion Efficiency Trend (2018–2026)
This chart illustrates how Immunovant Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immunovant Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunovant Inc ranked by their cash flow conversion efficiency. Explore how high is Immunovant Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NISSAN MOTOR SP. ADR/2
F:NISE
|
N/A |
|
Central Bancompany, Inc. Class A Common Stock
NASDAQ:CBC
|
0.026x |
|
Pegatron Corp
TW:4938
|
0.089x |
|
ICON Public Limited Company
F:IJF
|
0.042x |
|
South Bow Corporation
TO:SOBO
|
0.096x |
|
Nantong Jianghai Capacitor Co Ltd
SHE:002484
|
0.075x |
|
Stora Enso Oyj R
HE:STERV
|
0.003x |
|
Dosilicon Co Ltd
SHG:688110
|
-0.029x |
Annual Cash Flow Conversion Efficiency for Immunovant Inc (2018–2026)
The table below shows the annual cash flow conversion efficiency of Immunovant Inc from 2018 to 2026. View IMVT stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $852.59 Million | $-407.31 Million | -0.478x | +10.08% |
| 2025-03-31 | $707.45 Million | $-375.87 Million | -0.531x | -53.21% |
| 2024-03-31 | $617.76 Million | $-214.23 Million | -0.347x | +33.20% |
| 2023-03-31 | $362.49 Million | $-188.19 Million | -0.519x | -129.87% |
| 2022-03-31 | $469.82 Million | $-106.11 Million | -0.226x | -6.11% |
| 2021-03-31 | $391.48 Million | $-83.33 Million | -0.213x | +62.47% |
| 2020-03-31 | $94.07 Million | $-53.36 Million | -0.567x | +99.95% |
| 2019-03-31 | $24.55K | $-28.55 Million | -1162.716x | -1456.43% |
| 2018-03-31 | $-1.50 Million | $-128.30 Million | 85.719x | -- |
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinat… Read more